Ann: Dimerix Announces License Agreement for EU, Canada, ANZ, page-386

owl v fox, you seem to have posted a lot of well-informed comments on this stock. you mention travere in an earlier post. have you read their phase 3 sparsentan fgs study paper, it was published in New England journal a week ago. and what do you think is its importance to dmerix? it makes interesting reading including the comments from authors about why that trial wasn't successful.
I'd be thinking how TRavere does is very important to watch. from what I can see their trial shares lot of similarity with dmx fgs phase 3 trial, like the same endpoints and length. sparsentan seems to have got more convincing phase 2 results for proteinuria in fsg than the dmx2000 drug but still flopped on main gfr endpoint.
in my mind a key question now is what lessons dmerix and its partner takes from that Trevere trial as it goes through its own trial as could prove difference between success and failure. do you agree?